Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07222800 · ClinicalTrials.gov registry record · Phase 3
A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal Cancer
A Phase 3 study of Colorectal Neoplasms and Gastrointestinal Diseases, sponsored by Pfizer.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 800
- Enrollment target
- 16
- Study locations
NCT07222800: Recruiting Phase 3 study of Colorectal Neoplasms and Gastrointestinal Diseases, sponsored by Pfizer.
NCT07222800 is a Phase 3 study of Colorectal Neoplasms and Gastrointestinal Diseases that is actively recruiting participants, run by Pfizer. The registered enrollment target is 800 participants, above the 562-participant average among 54 other Colorectal Neoplasms trials with a reported enrollment target (42% higher). The trial reports 16 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07222800, a Phase 3 study of Colorectal Neoplasms and Gastrointestinal Diseases, is actively recruiting participants, sponsored by Pfizer.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 800 participants
- Enrollment target
- 16
- Study locations
Study Summary
The purpose of this study is to learn more about a new medicine called PF-08634404, and how well it works in people with cancer of the colon or rectum (CRC)). The goal is to understand if the new study medicine, combined with chemotherapy that is approved for colorectal cancer, can help people whose cancer has spread or returned after treatments taken before. To join the study, participants must meet the following conditions: * Be 18 years or older. * Have colorectal cancer that has spread to other parts of your body. * Be in good enough health to receive study treatment. * Should not be pregnant before starting treatment. Participants will be randomized (like flipping a coin) to one of 2 different treatment arms. The first arm (Arm A) will include the new medicine PF-08634404 in combination with chemotherapy that is approved for colorectal cancer, and the second arm (Arm B) will include an approved medicine for colorectal cancer, called Bevacizumab, in combination with chemotherapy that is approved for this type of cancer. Participants and their doctors will not know which arm they are being assigned to. Participants will receive all the study medications through intravenous (IV) infusions, which means the medicine is given directly into a vein. The treatment will be given in cycles, and participants may continue receiving it if it is helping and they are not experiencing serious side effects. The medicine will be given at a clinical site, where trained medical staff will check participants during and after each treatment. * The study is expected to last approximately 33 months for each participant. * Participants will have regular visits to the study site for treatment, health checks, and tests. * After stopping treatment, participants will return for a final visit about 30 to37 days later to check their health and review any side effects. * Follow-up will continue every 12 weeks by phone or in person or by reviewing health records to check on health status a
Primary Outcome
Progression-free survival is defined as the time from the date of randomization to the date of the first documentation of objective progressive disease (PD) assessed by BICR per RECIST 1.1, or death due to any cause, whichever occurs first.
Conditions Studied
Interventions
- DRUG Chemotherapy
- BIOLOGICAL Bevacizumab
- DRUG PF-08634404
Study Locations (16)
Other
- Icon Cancer Centre Wesley - Auchenflower
- Icon Cancer Centre Hobart - Hobart
- Kyushu University Hospital - Fukuoka
- Saitama Medical University International Medical Center - Hidaka
- National Hospital Organization Osaka Medical Center - Osaka
- Saitama Prefectural Cancer Center - Saitama
- The Cancer Institute Hospital of JFCR - Tokyo
- Pan American Center for Oncology Trials, LLC - Rio Piedras
Florida
- Mid Florida Hematology and Oncology Center - Orange City
- Cancer Care Centers of Brevard, Inc. - Palm Bay
Illinois
- Illinois Cancer Care - Canton
- Hope and Healing Cancer Services - Hinsdale
Texas
- Texas Oncology - West Texas - Odessa
- Texas Oncology - Northeast Texas - Tyler
New York
- Hematology Oncology Associates of Rockland - Nyack
Oregon
- Oncology Associates of Oregon, P.C. - Albany
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 800 participants |
| Start Date | 2025-12-11 |
| Est. Completion | 2031-08-01 |
| Phase | Phase 3 |
What NCT07222800 shows while recruiting
NCT07222800 is an interventional study that assigns participants to a tested intervention. The registered 800 participants enrollment target is mid-sized for trials with a published cap, above the 562-participant average among 54 other Colorectal Neoplasms trials with a reported enrollment target (42% higher).
The record links to 10 conditions, with Colorectal Neoplasms appearing as the primary indexed condition, and to 3 interventions - of which Chemotherapy is the first listed.
NCT07222800 lists 16 locations in 6 states (Other, Florida, Illinois).
Frequently Asked Questions
What is clinical trial NCT07222800 about?
NCT07222800 is a clinical study titled "A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal Cancer". The purpose of this study is to learn more about a new medicine called PF-08634404, and how well it works in people with cancer of the colon or rectum (CRC)). The goal is to understand if the new study medicine, combined with chemotherapy that is approved for colorectal cancer, can help people whose...
What is the current status of trial NCT07222800?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 800 participants. The study started on 2025-12-11. Estimated completion is 2031-08-01.
What conditions does trial NCT07222800 study?
This clinical trial studies the following conditions: Colorectal Neoplasms, Gastrointestinal Diseases, Gastrointestinal Neoplasms, Neoplasms by Site, Colonic Diseases.
What interventions are being tested in trial NCT07222800?
The interventions under investigation include: Chemotherapy (DRUG), Bevacizumab (BIOLOGICAL), PF-08634404 (DRUG).
Who is sponsoring clinical trial NCT07222800?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07222800 being conducted?
This trial has 16 study locations across Florida, Illinois, New York, Oregon, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Colorectal Neoplasms
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07222800's enrollment target sits among peer trials
800 7th of 54 higher than 48 of 54 other Colorectal Neoplasms trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Colorectal Neoplasms trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Performance of SGM-101 for the Delineation of Primary and Recurrent Tumor and Metastases in Patients Undergoing Surgery for Colorectal Cancer
RECRUITING · Phase 3
-
A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received Chemotherapy
RECRUITING · Phase 3
-
A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer
RECRUITING · Phase 3
-
A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer
RECRUITING · Phase 3
-
S0820, Adenoma and Second Primary Prevention Trial
ACTIVE NOT RECRUITING · Phase 3
-
Trial Of Irinotecan In Combination With Three Methods Of Administration Of Fluoropyrimidine.
COMPLETED · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00695214 · 800 participants · Phase 2
Drug-Induced Sleep Endoscopy for Upper Airway Evaluation in Obstructive Sleep Apnea
- NCT03048201 · 800 participants · NA
Physica System Total Knee Replacement Registry Study
- NCT03792659 · 800 participants
The EXPLORE MG Registry for Myasthenia Gravis
- NCT03819296 · 800 participants · Phase 1
Role of Gut Microbiome and Fecal Transplant on Medication-Induced GI Complications in Patients With Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI